Last Updated : May 10, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort ascending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Xeomin | Clostridium botulinum neurotoxin type A, free from complexing proteins | Blepharospasm | List in a similar manner | Complete | ||
| Xeomin | Clostridium botulinum neurotoxin type A, free from complexing proteins | Cervical Dystonia | List in a similar manner | Complete | ||
| Xeomin | Clostridium botulinum neurotoxin type A, free from complexing proteins | Spasticity, Post-stroke | Do not list | Complete | ||
| Clolar | clofarabine | Acute lymphoblastic leukemia | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| TBC | clindamycin plus benzoyl peroxide and adapalene | acne vulgaris | Active | |||
| Winlevi | clascoterone | Acne vulgaris | Withdrawn | |||
| Mavenclad | cladribine | Multiple Sclerosis, relapsing-remitting | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ciprodex | Ciprofloxacin hydrochloride and dexamethasone otic suspension | Otitis media with otorrhea & otitis externa, acute | Do not list | Complete | ||
| Ciprodex | Ciprofloxacin hydrochloride & dexamethasone otic suspension | Otitis media with otorrhea & otitis externa, acute | List with clinical criteria and/or conditions | Complete | ||
| Sensipar | Cinacalcet hydrochloride | Secondary hyper-parathyroidism in chronic kidney disease | Do not list | Complete |
Last Updated : May 10, 2024